Affymetrix completes $315 million eBioscience acquisition

Affymetrix Inc. said Monday it has completed its previously announced plans to purchase eBioscience Holding Co. Inc.

Santa Clara-based Affymetrix (NASDAQ:AFFX) said the purchase price was about $315 million in cash, funded through a new senior secured credit facility, an offering of convertible notes and other cash resources. The price is lower than a previously announced $330 million.

Affymetrix acquisition of eBioscience hits delay

Affymetrix Inc.'s previously announced acquisition of San Diego-based eBioscience Inc. has been delayed, according to StreetInsider.com on Wednesday.
The deal was previously expected to close in the fourth quarter of 2011, but is now expected to wrap up in January 2012. The delay is due to additional work required to complete the merger's debt financing, StreetInsider reports.

Affymetrix to buy eBioscience for $330M

Affymetrix Inc. said Wednesday it signed an agreement to acquire eBioscience Inc.
Santa Clara-based Affymetrix (NASDAQ:AFFX) said the purchase price is $330 million in cash, subject to certain customary adjustments. Affymetrix makes products and services related to genetic analysis for the life science research and clinical health care markets.
San Diego-based eBioscience is a private company specializing in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. EBioscience is expected to have 2011 sales of more than $70 million.